3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Colorectal Neoplasms
2
Recurrence
1
Polycystic Ovary Syndrome
1
Obesity
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Intraocular Lymphoma
1
Inflammation
1
Hodgkin Disease
1
Frailty
1
Corneal Endothelial Cell Loss
1
Cataract
1
Breast Neoplasms
1
Anemia
1
Interventions
pembrolizumab
49
Specimen Handling
29
Magnetic Resonance Spectroscopy
25
Biopsy
25
Radiosurgery
17
Gemcitabine
17
Nivolumab
16
Cyclophosphamide
14
Cisplatin
14
Paclitaxel
13
Carboplatin
13
Bevacizumab
13
Leucovorin
11
Irinotecan
11
Fluorouracil
11
Drug Therapy
11
Taxes
10
Radiotherapy
10
Oxaliplatin
10
Capecitabine
10
trastuzumab deruxtecan
9
fludarabine
9
cemiplimab
8
Doxorubicin
8
Cetuximab
8
abemaciclib
7
Trastuzumab
7
Pemetrexed
7
Fulvestrant
7
Docetaxel
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm Metastasis
×
Ascorbic Acid
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled